A PHASE 1/PHASE 2 STUDY OF CP-751,871 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY EWING’S SARCOMA FAMILY OF TUMORS

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 76

Inclusion Criteria

1.Phase 1: Male and female patients 10-18 years old. Phase 2: Male and female patients at least 10 years old. This is multiple center and multinational study. Individual investigators may elect to restrict enrollment to an older age cohort, eg, 13 years old or older, according to local institutional practices.
2.Phase 1 Dose Escalation: Histologically or cytologically confirmed (no new biopsy required) diagnosis of osteosarcoma, rhabdomyosarcoma, desmoplastic small round cell tumor (DSRCT) or any ESFT, ie, Ewing’s sarcoma, extra-osseous Ewing’s sarcoma, Askin’s and peripheral neuroectodermal tumors (PNET).
Phase 1 RP2D Extension: Sarcoma patients as defined in the Phase 1 Dose Escalation inclusion criterion. Upon opening of the Phase 2 portion of the study, Ewing’s sarcoma patients with at least one measurable lesion as defined by RECIST will be enrolled in the Phase 2 cohort. Ewing’s sarcoma patients with non RECIST measurable disease may be enrolled in the Phase 1 RP2D Extension cohort.
3.Phase 2: Histologically confirmed (no new biopsy required) ESFT tumor of the bone or soft tissue (Ewing’s sarcoma, extra-osseous Ewing’s sarcoma, PNET and Askin’s tumors).
4.Current disease state for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life.
5.Phase 2 only: At least one measurable lesion as defined by RECIST.
6.Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 2 or a Lansky score >50.
7.Adequate bone marrow function documented within 2 weeks prior to treatment, defined as:
•Absolute neutrophil count (ANC) ?1000/mL without growth factor support
•Platelets ?75,000/mL
•Hemoglobin ?8 g/dL (Previous transfusion is allowed)
8.Adequate renal, hepatic and cardiac functions documented within 2 weeks prior to study treatment, defined as:
•Total bilirubin <1.5 times the upper limit of normal (ULN) for age (except for Gilbert’s syndrome patients)
•Serum alanine aminotransferase (ALT) <2.5 ? ULN for age
•aspartate aminotransferase (AST) <2.5 ? ULN for age
•Serum creatinine ?1.5 x ULN for age
•Ejection Fraction =50%
9.Phase 1: Prior radiotherapy (more than 1 week prior to enrollment). Phase 2: Prior radiotherapy (more than 1 week prior to enrollment) is allowed provided is not at the only site of measurable disease. A measurable lesion that has been irradiated will be considered measurable only when it has increased in size. Patients must have recovered from all acute radiation toxicities (< Grade 1 or deemed irreversible) before enrollment.
10.Fully recovered (< Grade 1 or deemed irreversible) from the acute effects of prior cancer therapy before initiation of study treatment, including a recovery period of a minimum of 2 weeks since previous chemotherapy (8 weeks for mitomycin C or nitrosoureas) and 4 weeks from prior biologic therapy. Recovery from previous investigational therapy must be discussed with the Sponsor.
11.Sexually active female patients of childbearing age must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy up to 150 days after the last dose of CP-751,871. Acceptable contraception includes, but is not limited to: oral hormone therapy, IUD, condoms, caps (diaphragm) with spermicide, or partner vasectomy. The following forms are not acceptable: withdrawal method, rhythm method, spermicides, barrier sponge with or without spermicide. Within these limits, th

Exclusion Criteria

1.Concurrent treatment with any anti tumor agents.
2.Phase 2 only: Prior anti-IGF-IR therapy
3.Major surgery within 4 weeks prior to study treatment.
4.Patients with symptomatic brain metastases. Patients with previously diagnosed brain metastases are eligible if they have completed their CNS treatment and have recovered from the acute effects of radiation therapy or surgery prior to the start of study medication, have discontinued corticosteroid treatment for these metastases for at least 4 weeks, and are neurologically stable.
5.Breastfeeding females.
6.Significant active cardiac disease including: uncontrolled high blood pressure (no greater than 2 SD above the mean for age for SBP and DBP), unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, or serious cardiac arrhythmias.
7.Subjects who are receiving chronic high dose immunosuppressive steroid therapy within 2 weeks prior to enrollment (?100 mg prednisone per day or >40 mg dexamethasone per day).
8.Active infection.
9.Insulin-dependent diabetes.
10.History of malignancies not included in this protocol at sites other than curatively treated in situ carcinoma of the cervix of the uterus, or basal or squamous cell carcinoma of the skin.
11.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

Phase 1

Pfizer Inc, 235 East 42nd Street, New York, NY 10017

Updated 12/13/2021